Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2012 (2012), Article ID 620967, 5 pages
http://dx.doi.org/10.1155/2012/620967
Case Report

Allogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic Leukemia

1Cancer Molecular Diagnostics, Central Pathology Laboratory, St. James’s Hospital, Dublin 8, Ireland
2National Centre for Medical Genetics, Our Lady’s Children’s Hospital, Dublin 12, Ireland
3Department of Haematology, St. James’s Hospital, Dublin 8, Ireland

Received 11 July 2012; Accepted 2 September 2012

Academic Editors: E. Arellano-Rodrigo, N. Hamerschlak, K. Konstantopoulos, and K. Nakase

Copyright © 2012 Karl Haslam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. C. Jackson, L. J. Medeiros, and R. N. Miranda, “8p11 myeloproliferative syndrome: a review,” Human Pathology, vol. 41, no. 4, pp. 461–476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. B. J. Bain, D. G. Gilliland, H. -P. Horny, and J. W. Vardiman, “Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB and FGFR1,” in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, S. H. Swerdlow, E. Campo, and N. L. Harris, Eds., pp. 68–73, IARC, Lyon, France, 2008. View at Google Scholar
  3. A. Holroyd, N. C. P. Cross, and D. H. Macdonald, “The two faces of myeloproliferative neoplasms: molecular events underlying lymphoid transformation,” Leukemia Research, vol. 35, no. 10, pp. 1279–1285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Suzan, G. Guasch, C. Terre et al., “Long-term complete haematological and molecular remission after allogeneic bone marrow transplantation in a patient with a stem cell myeloproliferative disorder associated with t(8;13)(p12;q12),” British Journal of Haematology, vol. 121, no. 2, pp. 312–314, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Townsend, N. C. P. Cross, K. Waghorn et al., “Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder,” Bone Marrow Transplantation, vol. 44, no. 3, pp. 197–199, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Demiroglu, E. Joanna Steer, C. Heath et al., “The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins,” Blood, vol. 98, no. 13, pp. 3778–3783, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Fioretos, I. Panagopoulos, C. Lassen et al., “Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL,” Genes Chromosomes and Cancer, vol. 32, no. 4, pp. 302–310, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Pini, E. Gottardi, P. Scaravaglio et al., “A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p,” Hematology Journal, vol. 3, no. 6, pp. 315–316, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Murati, C. Arnoulet, M. Lafage-Pochitaloff et al., “Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion,” International Journal of Oncology, vol. 26, no. 6, pp. 1485–1492, 2005. View at Google Scholar · View at Scopus
  10. H. Ågerstam, H. Lilljebjörn, C. Lassen et al., “Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome,” Genes Chromosomes and Cancer, vol. 46, no. 7, pp. 635–643, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Richebourg, O. Theisen, I. Plantier et al., “Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia,” Genes Chromosomes and Cancer, vol. 47, no. 10, pp. 915–918, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. G. Lee, T. S. Park, S. T. Lee et al., “Rare translocations involving chromosome band 8p11 in myeloid neoplasms,” Cancer Genetics and Cytogenetics, vol. 186, no. 2, pp. 127–129, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Baldazzi, I. Iacobucci, S. Luatti et al., “B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene,” Leukemia Research, vol. 34, no. 10, pp. e282–e285, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. M. Patnaik, N. Gangat, R. A. Knudson et al., “Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution,” American Journal of Hematology, vol. 85, no. 4, pp. 238–242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Y. Kim, B. Oh, C. J. She et al., “8p11 myeloproliferative syndrome with BCR-FGFR1 rearrangement presenting with T-lymphoblastic lymphoma and bone marrow stromal cell proliferation: a case report and review of the literature,” Leukemia Research, vol. 35, no. 5, pp. e30–e34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. J. J. Wakim, C. A. Tirado, W. Chen, and R. Collins, “T(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature,” Leukemia Research, vol. 35, no. 9, pp. e151–e153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Dolan, A. Cioc, N. C. P. Cross, J. P. Neglia, and J. Tolar, “Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion,” Pediatric Blood & Cancer, vol. 59, no. 1, pp. 194–196, 2011. View at Google Scholar
  18. J. J. M. Van Dongen, E. A. Macintyre, J. A. Gabert et al., “Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia,” Leukemia, vol. 13, no. 12, pp. 1901–1928, 1999. View at Google Scholar · View at Scopus
  19. A. Qureshi, C. Mitchell, S. Richards, A. Vora, and N. Goulden, “Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe,” British Journal of Haematology, vol. 149, no. 3, pp. 410–413, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. R. McCann, M. Crampe, K. Molloy, and M. Lawler, “Hemopoietic chimerism following stem cell transplantation,” Transfusion and Apheresis Science, vol. 32, no. 1, pp. 55–61, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Ren, J. A. Tidwell, S. Sharma, and J. K. Cowell, “Acute progression of BCR-FGFR1 induced murine B-lympho/myeloproliferative disorder suggests involvement of lineages at the pro-B cell stage,” PLoS ONE, vol. 7, no. 6, Article ID e38265, 2012. View at Google Scholar
  22. S. Roumiantsev, D. S. Krause, C. A. Neumann et al., “Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations,” Cancer Cell, vol. 5, no. 3, pp. 287–298, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Perrotti, C. Jamieson, J. Goldman, and T. Skorski, “Chronic myeloid leukemia: mechanisms of blastic transformation,” Journal of Clinical Investigation, vol. 120, no. 7, pp. 2254–2264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Chase, F. H. Grand, and N. C. P. Cross, “Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome,” Blood, vol. 110, no. 10, pp. 3729–3734, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Wasag, E. Lierman, P. Meeus, J. Cools, and P. Vandenberghe, “The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11),” Haematologica, vol. 96, no. 6, pp. 922–926, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Chen, D. J. DeAngelo, J. L. Kutok et al., “PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 40, pp. 14479–14484, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. J. J. Wakim, C. A. Tirado, W. Chen, and R. Collins, “T(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature,” Leukemia Research, vol. 35, no. 9, pp. e151–e153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Lierman, S. Smits, J. Cools, B. Dewaele M, Debiec-Rychter, and P. Vandenberghe, “Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases,” Leukemia, vol. 26, no. 7, pp. 1693–1695, 2012. View at Google Scholar
  29. M. Ren, H. Qin, R. Ren, and J. K. Cowell, “Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities,” Leukemia. In press. View at Publisher · View at Google Scholar
  30. A. Chase, C. Bryant, J. Score, and N. C. Cross, “Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome,” Haematologica. In press. View at Publisher · View at Google Scholar